News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
<Research>Citi Lifts WUXI APPTEC (02359.HK) TP to $158.5 w/ Rating Buy
Citi Research issued a research report lifting its target prices for WUXI APPTEC (02359.HK)'s H-/ A-shares from $156/ RMB138 to $158.5/ RMB140, with ratings at Buy, reflecting ...
Reset
Send
The window will close in 5 seconds
<Research>Citi Lifts WUXI APPTEC (02359.HK) TP to $158.5 w/ Rating Buy
Close
Recommend
9
Positive
10
Negative
7
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

Citi Research issued a research report lifting its target prices for WUXI APPTEC (02359.HK)  +4.800 (+3.825%)    Short selling $414.42M; Ratio 28.123%   's H-/ A-shares from $156/ RMB138 to $158.5/ RMB140, with ratings at Buy, reflecting a 2% upward revision to revenue and EPS forecasts, based on Citi Research's optimistic outlook for Eli Lilly and Company (LLY.US)      's tirzepatide and orforglipron projects.

The broker estimated that these projects will drive robust growth in WUXI APPTEC's TIDES business, forecasting a 40% YoY growth rate for the segment in 2026.

Citi Research also estimated that, if orforglipron is launched in China in 2027, PHARMARON (03759.HK)  +0.130 (+0.748%)    Short selling $15.07M; Ratio 13.845%   will benefit, as its cooperation with Eli Lilly could further expand from orforglipron DP manufacturing in China.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-29 16:25.) (Real-time Streaming US Stocks Quote; Except All OTC quotes are at least 15 minutes delayed.)

Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.